GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

CHICAGO - Monday, 05. October 2026


    Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
    Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
    Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1

 

(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.

The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals. It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.

“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado™ (flurpiridaz F18 injection) product,” said Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare. “We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences, helping improve patient access, strengthen reliability of supply, and support the next generation of precision care products."

PET radiopharmaceuticals are used in precision medicine to visualize metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas. F18 labeled PET radiopharmaceuticals have a 110-minute half-life, with PET CMOs playing a crucial role in enabling timely and reliable patient access, both to existing and pipeline products. Industry-wide, the radiopharmaceutical pipeline is growing rapidly, with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development.2 These include SOFIE Biosciences’ Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI) asset, FAPI-74, for which GE HealthCare already holds outside-of-U.S. rights. FAPI has the potential to further expand an already fast-growing global PET imaging market, and is showing strong potential for diagnostic and theranostic use across a range of oncologic and non-oncologic indications.

GE HealthCare will continue to drive and expand access to its existing proprietary F18 radiopharmaceutical products, while advancing its pipeline of new products, both through SOFIE Biosciences, and PDx’s other established CMO partners across the U.S.

Serving SOFIE Biosciences’ Customers

Following the transaction close, SOFIE Biosciences will continue to operate as an independent manufacturing partner to its customers, supplying its existing product portfolio, including products from other leading radiopharmaceutical providers.

Patrick Phelps, SOFIE Biosciences co-founder, President & CEO, said, “As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”

Ted Rosenwasser, Partner, Trilantic North America, said, "We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare's legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support 140 million procedures in 2025, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare's imaging agents have been routinely used across care pathways to support diagnosis.

Financial Benefits

GE HealthCare estimates that the transaction will be accretive to revenue growth, Adjusted earnings before interest and taxes margin* and Adjusted earnings per share* in the first full year of ownership.

Advisors

For GE HealthCare, BofA Securities, Consello Financial LLC and Solomon Partners Securities LLC served as financial advisors.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

About SOFIE Biosciences

SOFIE Biosciences' mission is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With a robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and high-value Theranostic intellectual property, SOFIE Biosciences is delivering on the promise of radiopharmaceuticals. For more information, please visit www.sofie.com or info@sofie.com.

About Trilantic North America

Trilantic Capital Management L.P. ("Trilantic North America") is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America's primary investment focus is in the business and consumer services sectors. Since inception, Trilantic North America has managed seven private equity fund families, representing $11.6B in raised capital commitments. For more information, visit www.trilanticnorthamerica.com.

*Non-GAAP financial measure; see our earnings release dated July 29, 2026 for definitions.

References:

1. https://researchintelo.com/report/fapi-pet-imaging-market
2. MEDraysintell Report, 2025 Edition

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005273717/en/

Permalink
https://www.aetoswire.com/en/news/54616110

Contacts

GE HealthCare Media Contact
Emmy Elguizaoui
+1-978-243-7503
emmy.elguizaoui@gehealthcare.com

GE HealthCare Investor Relations Contact
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com

SOFIE Biosciences / Trilantic North America
Prosek Partners
Pro-trilantic@prosek.com

Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt

 In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probe

Designed, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on Justitia

Thought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planets

Watch the EMA hero film here

 

The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe.  

Designed, built and tested end-to-end in Abu Dhabi by TII’s Propulsion and Space Research Center, in collaboration with the UAE Space Agency, as well as HEX20, Khalifa University and UAE University’s National Space Science and Technology Center, the TII-built probe is the mission’s only deployable payload. It will separate from MBR Explorer to make contact with Justitia’s surface at the furthest point of the mission and operate fully autonomously in deep space, capturing close-range images and excavating its surface to provide new insights into its composition and physical characteristics. 269 Justitia is thought to have formed in the Kuiper Belt before migrating into the main asteroid belt during the early formation of the Solar System.

H.E. Faisal Al Bannai, Secretary General, Advanced Technology Research Council, the Abu Dhabi Government entity overseeing TII, and Member of the UAE Supreme Space Council, said: “If you want to build serious technological capability, you take on a problem that forces you to push further. For this mission, that means a probe that must make decisions and operate on its own in deep space. And our teams have built that technology here in the UAE. The mission might still be ahead, but we have already expanded what we know how to build. That is how sovereign capability grows. We solve a difficult problem, then set our sights on a bigger one.”

269 Justitia is among the reddest bodies ever observed in the main asteroid belt. Its spectrum more closely resembles objects in the Kuiper Belt beyond Neptune than neighboring asteroids, suggesting it may have formed in the cold outer Solar System, beyond the distance at which methane and methanol freeze, before migrating inward early in the Solar System’s history to its current orbit in the main asteroid belt.  Its surface is thought to be covered in complex organic material produced by the irradiation of that ice. Reaching such a body without a decade-long voyage to the Kuiper Belt itself gives the international scientific community access to material that is otherwise far beyond practical reach, and to evidence bearing on how water and volatiles were distributed as the planets formed.

Dr. Najwa Aaraj, Chief Executive Officer, TII, said: “EMA Probe demonstrates what becomes possible when advanced research is translated into mission-ready engineering. Our teams at TII have developed a system designed to withstand extreme conditions, operate with exceptional precision, and deliver meaningful science billions of kilometers from Earth. The mission reflects not only the caliber of our talent, but the depth of scientific and engineering capability the UAE has built to contribute to some of the world’s most ambitious space missions.”

The MBR Explorer spacecraft will travel approximately 5 billion kilometers over eight years, using gravity-assist maneuvers at Venus, Earth and Mars, and conducting close encounters with six asteroids before arriving at 269 Justitia. The spacecraft is scheduled to launch from Japan in March 2028 within a narrow three-week launch window aligned to interplanetary conditions. Because the spacecraft itself cannot safely approach within a few kilometers of the surface, the probe will separate, make contact with the surface, and deliver the mission’s closest observations.

Dr. Elias Tsoutsanis, Chief Researcher, Propulsion and Space Research Center, TII, said: “The engineering challenge is not simply reaching Justitia, but ensuring the probe can survive an eight-year journey and still perform precisely when it matters most. Every element – from the hardware and thermal design to the onboard software – has been engineered and tested for that final encounter.”

The probe operates fully autonomously throughout its mission, receiving no command from Earth or the MBR Explorer spacecraft after launch. Its onboard software determines when to image, how many images to capture, and which are worth keeping, a capability that rests on the digital processing unit designed and developed by TII – the board that handles the probe’s processing, image selection and power management. The probe does not wait until reaching Justitia to begin; it images throughout the cruise alongside the spacecraft’s other payloads, transmitting data back at approximately six-month intervals. Two cameras, one wide-field and one narrow-field, cover both context and high-resolution data.  

Dr. Anton Ivanov, Principal Investigator and Executive Director, Propulsion and Space Research Center, TII, said: “What makes this probe distinctive is the level of independence engineered into such a compact system. Once deployed, it must sense, decide and operate on its own, far beyond Earth. The program has also helped train Emirati engineers and strengthen the advanced capabilities needed to build a globally competitive space technology ecosystem in the UAE.”

On arrival, the MBR spacecraft will spend approximately seven months in orbit around Justitia, beginning at 250 kilometers and descending through a series of lower orbits. The probe will deploy during a low-altitude pass in early 2036, then descend and make contact with the surface, imaging continuously and transmitting to the spacecraft above. The subsequent images will then allow scientists to study material beneath the surface layer that cannot be characterized from orbit.

EMA is the UAE’s second interplanetary mission and the first in which the spacecraft element has been designed, engineered, assembled and tested within the country. The mission sits within a broader national commitment to the sector. In May 2026, the Supreme Space Council approved a AED 1 billion International Space Cooperation Program intended to connect UAE research institutions with counterparts internationally, localize advanced space technologies, and develop Emirati talent, in support of the National Space Strategy 2031.

For more information, visit www.tii.ae 

Permalink

https://www.aetoswire.com/en/news/tii02102026e

Contacts

Thushara Mohanan, thushara.mohanan@tii.ae

LTM Launches BlueVerse™ AgenTraceIQ

 MUMBAI, India - Monday, 05. October 2026

Offering stems from Rubrik’s Project Hourglass, an alliance helping organizations scale agentic AI securely

 

(BUSINESS WIRE)--LTM, the Business Creativity partner to the world's largest enterprises, today announced the launch of BlueVerse™ AgenTraceIQ, an offering designed to help organizations securely adopt and scale agentic AI. Combining Rubrik Agent Cloud with LTM's AI governance and managed services expertise, the offering enables organizations to monitor AI agents, establish guardrails, and rewind unintended agent actions across business-critical environments.

As part of Rubrik’s Project Hourglass, LTM and other elite Global Systems Integrators partner with Rubrik, the Security and AI Operations Company, to deliver Rubrik Agent Cloud for Anthropic's Claude Code to their enterprise clients. The collaboration strengthens the ability for organizations to adopt agentic systems with the necessary security, governance, and resilience at scale.

"As AI agents increasingly act autonomously, the stakes for enterprise security and resilience have never been higher. Together with LTM, we are empowering organizations to move from reactive risk management to a proactive, secure framework, ensuring they can innovate with AI at speed without compromising their operational integrity." — Alok Agrawal, Chief Solutions Officer, Rubrik.

As AI agents become increasingly embedded in enterprise operations, organizations need a structured approach to managing risk, accountability, and operational continuity. Scaling beyond experimentation requires greater oversight of agent behaviour, stronger policy enforcement, and the ability to respond quickly when unexpected outcomes occur.

BlueVerse™ AgenTraceIQ addresses these challenges through an integrated framework that combines agent observability, governance, and resilience. Powered by Rubrik Agent Cloud and operationalized through LTM's governance-led services model, the offering brings together enterprise-ready advisory, deployment, and managed services to support responsible AI adoption at scale.

The solution provides continuous visibility into agent activity, enforces policy-driven controls and zero-trust access, and enables rapid restoration of systems, data, configurations, and repositories following unintended or destructive actions. By linking agent actions to prompts, plans, and tool interactions, it enhances explainability, auditability, and root-cause analysis. BlueVerse™ AgenTraceIQ supports leading agent ecosystems, including Microsoft Copilot Studio, Salesforce Agentforce, Amazon Bedrock, Anthropic Claude, and custom-built frameworks.

"Agentic AI is rapidly reshaping enterprise operations, but scaling adoption requires more than deploying intelligent agents. Organizations need the ability to understand agent behaviour, establish accountability, and respond quickly when unexpected outcomes occur. Together with Rubrik, BlueVerse™ AgenTraceIQ helps enterprises move from experimentation to trusted, production-scale AI operations," said Krishnan Iyer, Chief Growth Officer, LTM.

The offering also includes AI Resilience Assessments, Governance Framework Design, Deployment & Integration Services, and Managed Governance Operations, helping organizations establish enterprise-ready operating models for agentic AI. By combining Rubrik's technology with LTM's AI transformation expertise, BlueVerse™ AgenTraceIQ enables organizations to accelerate adoption, strengthen compliance readiness, and improve operational certainty as AI becomes embedded across the business.

To learn more about BlueVerse™ AgenTraceIQ , click here.

About LTM

LTM — a Larsen & Toubro Group Company — is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation and business AI — enabling new ways of working, new productivity paradigms and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

RUBRIK® and the Rubrik logo are registered trademarks of Rubrik, Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260925050912/en/

Permalink

https://www.aetoswire.com/en/news/54610941

Contacts

Media Contact: Gitanjali Sreepal | Global Media Relations | gitanjali.sreepal@ltm.com

JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope

 TOKYO -

(BUSINESS WIRE) -- JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026.

HAXIS Low-angle Ion Milling Scanning Electron Microscope

Background of development

As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods.

JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques.

HAXIS is JEOL's new semiconductor failure analysis platform that combines such technologies.

It has realized clear and highly reproducible PVC observation even with advanced semiconductors. By visually detecting electrical anomalies while minimizing the effects of processing damage and contamination, it is possible to efficiently identify the defect location and determine the cause. The use of argon (Ar), an inert gas, ensures stable surface quality and reduces running costs.

The quality of PVC observation is significantly affected by the surface condition of the sample after delayering. HAXIS uses a unique Low-Angle Ion Milling (LIM) delayering technique using Ar ion beams to create a flat surface with minimal damage to the sample surface. This enables clear and highly reproducible PVC observation while retaining structure and potential information even in advanced devices.

Semiconductor failure analysis involves multiple steps, from defect localization to physical analysis and root-cause investigation. As device complexity increases, shortening the turnaround time from failure detection to actionable results becomes increasingly critical.

HAXIS introduces a new approach to failure localization by integrating LIM delayering with SEM imaging and passive voltage contrast (PVC) analysis. This combined workflow enables rapid and highly accurate identification of failure locations, supporting QTAT (Quick Turnaround Time) failure analysis and accelerating the transition from electrical failure detection to physical analysis and root-cause identification.

Main features

Clear PVC imaging

Cost effective Ar processing

Damageless Delayering with LIM

Layer-by-layer LIM / PVC Analysis

Contamination free transfer

Sales target

15 units / year

Product Overview

HAXIS LIM-SEM Multi Beam System

https://www.jeol.com/products/scientific/sem/haxis.php

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260928207899/en/

Permalink

https://aetoswire.com/en/news/0510202657797

Contacts

JEOL Ltd.

3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan

Izumi Oi, President & CEO

(Stock code: 6951, Tokyo Stock Exchange Prime Market)

https://www.jeol.com/

JEOL Ltd.

SI Sales Division

webmaster@jeol.co.jp

https://www.jeol.com/contacts/products.php

 

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

 LEXINGTON, Mass. - Monday, 05. October 2026 AETOSWire  

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit

Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer

 

(BUSINESS WIRE) -- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada.

Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive and off all therapy.

These results come from a population with substantial prior treatment. Patients had received a median of four prior lines of therapy, and 66% had received at least four. All had previously received platinum chemotherapy, 77% had received bevacizumab and 57% had received a PARP inhibitor. Nearly three-quarters had platinum-resistant or refractory disease, meaning their cancer had progressed during platinum treatment or returned within six months of it.

“In recurrent ovarian cancer, conventional checkpoint immunotherapy has rarely produced lasting benefit, particularly after the disease stops responding to platinum chemotherapy,” said Rebecca L. Porter, MD, of Dana-Farber Cancer Institute, who presented the data. “What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments. That pattern suggests that a different approach to activating the immune system may offer some patients lasting benefit, even when treatment options have narrowed.”

Three-year follow-up findings

Overall efficacy results (n=35)

Overall survival (OS): Estimated survival was 48% at both two and three years. Median OS was 14.8 months.

Objective response rate (ORR): 23% of patients (8/35) had a response, including one complete response and seven partial responses.

Duration of response: Responses lasted a median of 9.7 months.

Clinical benefit: 31% of patients (11/35) had a response or stable disease lasting at least 24 weeks.

Alive and off treatment: At last follow-up, 25% (11 of all 44 patients who received at least one dose of treatment) were alive and off all therapy.

Results by patient subgroup

Platinum-resistant or refractory disease (n=25): Estimated three-year survival was 47%. ORR was 20% (5/25), including one complete and four partial responses.

Platinum-sensitive disease (n=10): Estimated three-year survival was 45%. Thirty percent (3/10) of patients had a partial response.

Four or more prior lines of therapy (n=23): Estimated three-year survival was 48%. ORR was 17% (4/23), with all four responses being partial responses.

Disease progression on a PARP inhibitor (n=17): In patients whose cancer had progressed during PARP inhibitor treatment or maintenance, estimated three-year survival was 61%. Two patients (12%) had partial responses.

Safety remained consistent with the known BOT+BAL profile. No new safety signals or treatment-related deaths were reported.

“The most compelling finding is that the survival curve extends beyond two years in women who had already received multiple treatments, including those with platinum-resistant or refractory disease,” said Steven J. O’Day, MD, Chief Medical Officer of Agenus. “We have seen a similar pattern of durable survival in other difficult-to-treat cancers studied with BOT+BAL. This three-year ovarian update strengthens our conviction that the combination can deliver meaningful, lasting benefit to a subset of patients who have had few effective immunotherapy options.”

The three-year ovarian results add to a pattern of long-term survival across difficult-to-treat cancers studied with BOT+BAL. In the broader 400+ patient Phase 1b pan-tumor analysis, estimated two-year survival was 39%. In a separate cohort of patients with refractory MSS metastatic colorectal cancer without active liver metastases, estimated survival was 41% at two years and 33% at three years. These findings are particularly notable in cancers where conventional immunotherapy has historically offered limited benefit.

The consistent and durable BOT+BAL activity in heavily pretreated cancers that are poorly immunogenic or resistant to prior immunotherapy, reinforced by deep pathologic responses in neoadjuvant studies, strengthens the rationale for moving treatment earlier in the course of disease. Before surgery, when the primary tumor and surrounding lymph nodes remain intact, BOT+BAL may have the greatest opportunity to generate lasting antitumor immunity, reduce recurrence and ultimately increase the number of patients who may be cured.

The full presentation can be found on the publications section of the Agenus website at www.agenusbio.com/publications.

BOT and BAL are in development and have not been approved by the U.S. Food and Drug Administration.

Presentation details

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival

Presenter: Rebecca L. Porter, MD; Dana-Farber Cancer Institute, Boston, MA, USA

Poster Presentation number: 969

Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session

Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

About the C-800-01 Study

C-800-01 (NCT03860272) is a multicenter Phase 1b trial evaluating BOT with or without BAL in advanced solid tumors. The ovarian cancer cohort included patients with recurrent disease for whom no standard therapy was available or whose cancer had progressed after standard treatment. The efficacy analysis included 35 patients who had at least one tumor scan after starting therapy. The safety population included all 44 patients who received treatment. The data cutoff for this analysis was December 13, 2025.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Agenus’ Commitment to Patient Access

Until marketing authorization is granted, BOT+BAL is accessible only through clinical trials and authorized early access mechanisms where permitted and available under each country’s regulatory framework. For eligible French patients treated in hospitals under AAC and meeting the predefined criteria, BOT+BAL is fully reimbursed by France’s national health system. Outside France, access may be available in select countries through paid named-patient programs, which may involve out-of-pocket costs to the patient or coverage under applicable national or private reimbursement arrangements. These programs are physician-driven and are not promotional.

About Botensilimab (BOT)

Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.

Approximately 1,500 patients have been treated with BOT and balstilimab (BAL) in phase 1 and phase 2 clinical trials. The combination with Agenus’ investigational PD-1 antibody, BAL, has shown clinical responses across more than nine cancers. For more information about BOT trials, visit www.clinicaltrials.gov.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261003256338/en/

Permalink

https://www.aetoswire.com/en/news/0510202657782

Contacts

Investors

917-362-1370 | investor@agenusbio.com

Media

781-674-4422 | communications@agenusbio.com

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement

 ARLINGTON, Va. - 

(BUSINESS WIRE) -- Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030.

"Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come."

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing carbon capture and sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, however they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001098196/en/

Permalink

https://www.aetoswire.com/en/news/0210202657758

Contacts

Investor Contact:

Ben Nolan

IR@ventureglobalLNG.com

Media Contact:

Shaylyn Hynes

press@ventureglobalLNG.com

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising

 

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store.

 

(BUSINESS WIRE)--NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access.

"Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivity, respond faster to change, and make more confident merchandising decisions at scale."

Key client benefits

Work more efficiently with NIQ Optiq: Use conversational AI to create and optimize planograms through natural-language requests within Spaceman, reducing manual effort and helping merchandising teams complete traditionally time-intensive planning tasks more efficiently.

Localize store-specific planograms at scale: Use Spaceman’s automation capabilities to create and maintain store-specific planograms across large store networks, accounting for local market conditions, assortments, and shopper behavior to bring greater localization to the shelf at scale.

Improve execution through AI-powered compliance measurement: Automatically identify execution gaps and compliance issues across stores, reducing manual audits and driving a more consistent shopper experience.

These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency, consistency, and business impact across their operations.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

Spaceman® and NIQ® are registered trademarks (NIQ with additional pending applications); NIQ Optiq and The Full View™ are pending trademarks; all of Nielsen Consumer LLC or its affiliates. NielsenIQ® is a registered trademark licensed to NIQ. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements regarding anticipated timelines, benefits, features, and outcomes of the latest Spaceman enhancements. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as 'expects,' 'anticipates,' 'projects,' 'believes,' 'forecasts,' and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

© 2026 Nielsen Consumer LLC. All Rights Reserved.

Frequently Asked Questions

Q: What is changing with Spaceman®?

A: NIQ is investing in Spaceman to deliver a more scalable, cloud-enabled, and AI-powered merchandising solution. The latest enhancements combine cloud-based delivery, AI/ML-powered capabilities, and enhanced automation to help retailers and manufacturers plan faster, execute better, and grow smarter while turning merchandising decisions into measurable business outcomes.

Q: Why is NIQ investing in Spaceman?

A: Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior. These investments are designed to reduce manual planning effort, help retailers scale localized merchandising decisions, and improve execution across large store networks.

Q: What makes the latest evolution of Spaceman different?

A: The latest evolution brings conversational AI, planogram automation, modeling, compliance measurement, and cloud-based access together within the Spaceman merchandising workflow. This enables retailers to move more efficiently from planning to store-specific execution while scaling decisions across their store networks.

Q: How does Spaceman help retailers?

A: Spaceman helps retailers create and maintain localized, store-specific planograms at scale, reduce manual planning effort, and improve visibility into merchandising execution and compliance. This helps teams respond more effectively to local market conditions, assortments, and shopper behavior while delivering greater consistency across their store networks.

Q: How does cloud-based access support Spaceman clients?

A: NIQ-managed Azure hosting enables clients to operate Spaceman on NIQ-managed cloud infrastructure, reducing reliance on internal IT resources while improving scalability, deployment speed, and overall platform performance.

Q: What AI capabilities are included in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling merchandising teams to use natural-language requests to create and optimize planograms with less manual effort. Spaceman also uses AI and machine learning to support planogram automation and compliance measurement, helping retailers localize merchandising at scale and identify execution gaps across stores.

Q: What is NIQ Optiq in Spaceman?

A: NIQ Optiq brings conversational AI into Spaceman, enabling users to translate natural-language requests into planogram actions. It works with the data already managed within Spaceman and its existing automation and machine learning capabilities to help merchandising teams create and optimize planograms with less manual effort.

Q: Who can benefit from Spaceman?

A: Spaceman is designed for retailers looking to modernize merchandising operations, improve planogram creation and execution, reduce manual effort and IT complexity, and scale localized, data-driven merchandising decisions across their store networks.

Q: What types of business decisions can Spaceman support?

A: Spaceman supports decisions across assortment planning, space planning, store-specific planogram creation, merchandising execution, compliance measurement, and category management. By connecting planning and execution, Spaceman helps retailers make more localized and consistent merchandising decisions across their store networks.

Q: How does Spaceman support NIQ's broader strategy?

A: These investments reflect NIQ's broader commitment to embedding trusted AI across retail workflows and delivering cloud-enabled solutions that help retailers move more seamlessly from planning to execution. By connecting intelligent automation, merchandising decisions, and execution measurement, NIQ is helping retailers drive greater efficiency and consistency across their operations.

Q: Is this the final phase of Spaceman's evolution?

A: No. The latest enhancements represent the next step in NIQ's ongoing investment in Spaceman. NIQ will continue to evolve the platform to help retailers simplify merchandising, improve execution, and respond more effectively to changing market conditions.

NIQ-GENERAL

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001493563/en/

Permalink

https://www.aetoswire.com/en/news/54613412

Contacts

Media contact: Julia Mayer

julia.mayer@nielseniq.com